Pancreatic Cancer Research

ResearcherUniversity of MiamiNo recent work listed

Bhuwan Giri

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2130-2425; OpenAlex author ID A5053379382. Sources: OpenAlex.

Their work

Papers
13 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
32
Papers, trials and grants by year

2016: 3 papers · 2017: 2 papers · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 2 papers · 2022: 2 papers

Papers 13

  1. Minnelide synergizes with conventional chemotherapy by targeting both cancer and associated stroma components in pancreatic cancer. First author DOI 10.1016/j.canlet.2022.215591↗
  2. Prescription patterns of pancreatic enzyme replacement therapy for patients with pancreatic cancer in the United States. Co-author DOI 10.1016/j.hpb.2022.05.003↗
  3. An Immunocompetent Model of Pancreatic Cancer Resection and Recurrence. Co-author DOI 10.1007/s11605-020-04681-9↗
  4. Hsp70 modulates immune response in pancreatic cancer through dendritic cells. Co-author DOI 10.1080/2162402x.2021.1976952↗
  5. Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy. Co-author DOI 10.1172/jci127515↗
  6. Targeting tumor intrinsic metabolic node in pancreatic cancer causes tumor regression,remodels extracellular matrix and sensitizes to anti-PD1 therapy Co-author DOI 10.1016/j.pan.2019.05.430↗
  7. O-GlcNAc modification of Sox2 regulates self-renewal in pancreatic cancer by promoting its stability. Co-author DOI 10.7150/thno.32615↗
  8. Metastasis and chemoresistance in CD133 expressing pancreatic cancer cells are dependent on their lipid raft integrity. Co-author DOI 10.1016/j.canlet.2018.09.028↗
  9. Modulation of post-translational modifications in β-catenin and LRP6 inhibits Wnt signaling pathway in pancreatic cancer. First author DOI 10.1016/j.canlet.2016.11.026↗
  10. Inhibition of Sp1 prevents ER homeostasis and causes cell death by lysosomal membrane permeabilization in pancreatic cancer. Co-author DOI 10.1038/s41598-017-01696-2↗
  11. A Novel Immunocompetent Mouse Model of Pancreatic Cancer with Robust Stroma: a Valuable Tool for Preclinical Evaluation of New Therapies. Co-author DOI 10.1007/s11605-015-2985-y↗
  12. Minnelide Overcomes Oxaliplatin Resistance by Downregulating the DNA Repair Pathway in Pancreatic Cancer. Co-author DOI 10.1007/s11605-015-3000-3↗
  13. Inhibition of NF-kappa B pathway leads to deregulation of epithelial-mesenchymal transition and neural invasion in pancreatic cancer. Co-author DOI 10.1038/labinvest.2016.109↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Vikas Dudeja · 13 shared papers, 2016–2022 · strength 1.18
  2. Ashok Kumar Saluja · 12 shared papers, 2016–2022 · strength 1.05
  3. Sulagna Banerjee · 10 shared papers, 2016–2021 · strength 0.80
  4. Vineet Kumar Gupta · 6 shared papers, 2017–2022 · strength 0.57
  5. Nikita Sharma · 6 shared papers, 2017–2022 · strength 0.57
  6. Vrishketan Sethi · 4 shared papers, 2021–2022 · strength 0.50
  7. Anthony R. Ferrantella · 4 shared papers, 2019–2021 · strength 0.41
  8. Shrey Modi · 4 shared papers, 2016–2022 · strength 0.38
  9. Kousik Kesh · 4 shared papers, 2018–2020 · strength 0.35
  10. Tejeshwar Jain · 3 shared papers, 2021–2022 · strength 0.35
  11. Prateek Sharma · 3 shared papers, 2021–2022 · strength 0.35
  12. Patricia Dauer · 4 shared papers, 2016–2019 · strength 0.29
  13. Sundaram Ramakrishnan · 3 shared papers, 2016–2021 · strength 0.27
  14. Kaustav Majumder · 4 shared papers, 2016–2017 · strength 0.26
  15. Alice Nomura · 4 shared papers, 2016–2018 · strength 0.26
  16. Nipun B. Merchant · 2 shared papers, 2021–2022 · strength 0.24
  17. Selwyn Maurice Vickers · 2 shared papers, 2019–2022 · strength 0.24
  18. Utpreksha Vaish · 2 shared papers, 2021–2022 · strength 0.23
  19. Srikanth Iyer · 2 shared papers, 2021–2022 · strength 0.23
  20. Harrys K.C. Jacob · 2 shared papers, 2021 · strength 0.22
  21. Bharti Garg · 2 shared papers, 2017–2021 · strength 0.19
  22. Santanu Banerjee · 2 shared papers, 2018–2019 · strength 0.16
  23. Somnath Pandey · 1 shared paper, 2022 · strength 0.15
  24. Shweta Lavania · 1 shared paper, 2022 · strength 0.15
  25. John Bart Rose · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.